Research Papers:
CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response
Metrics: PDF 1509 views | HTML 2502 views | ?
Abstract
Alini Trujillo-Paolillo1,2, Francine Tesser-Gamba1, Antonio Sergio Petrilli3, Maria Teresa de Seixas Alves4, Reynaldo Jesus Garcia Filho5, Renato de Oliveira6 and Silvia Regina Caminada de Toledo1,2,7
1Genetics Laboratory, Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Rua Botucatu, Vila Clementino, Sao Paulo SP, 04023-062, Brazil
2Department of Clinical and Experimental Oncology, Federal University of Sao Paulo, Rua Dr. Diogo de Faria, Vila Clementino, Sao Paulo SP, 04037-003, Brazil
3Pediatric Oncology Institute (IOP/GRAACC), Department of Pediatrics, Federal University of Sao Paulo, Rua Botucatu, Vila Clementino, Sao Paulo SP, 04023-062, Brazil
4Department of Pathology, Federal University of Sao Paulo, Rua Botucatu, Vila Clementino, Sao Paulo SP, 04023-062, Brazil
5Department of Orthopedic Surgery and Traumatology, Federal University of Sao Paulo, Rua Borges Lagoa, Vila Clementino, Sao Paulo SP, 04038-031, Brazil
6Department of Thoracic Surgery, Federal University of Sao Paulo, Rua Napoleao de Barros, Vila Clementino SP, 04024-002, Brazil
7Department of Morphology and Genetics, Federal University of Sao Paulo, Rua Botucatu, Vila Clementino, Sao Paulo SP, 04023-062, Brazil
Correspondence to:
Silvia Regina Caminada de Toledo, email: [email protected]
Keywords: osteosarcoma, cytochrome P-450, osteosarcoma cell line, tumor microenvironment, treatment response
Received: March 22, 2016 Accepted: January 06, 2017 Published: March 03, 2017
ABSTRACT
Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents. The present study investigated the expression of Cytochrome P-450 (CYP) genes: CYP1A2, CYP3A4 and CYP3A5 by qRT-PCR in 135 specimens obtained from OS patients, including biopsy (pre-chemotherapy), tumor resected in surgery (post-chemotherapy), adjacent bone to tumor (nonmalignant tissue), pulmonary metastasis and adjacent lung to metastasis (nonmalignant tissue). Normal bone and normal lung tissues were used as control. We also investigated in five OS cell lines the modulation of CYPs expression by cisplatin, doxorubicin and methotrexate. As result, the adjacent lung specimens presented CYP1A2 overexpression compared to the normal lung (p=0.0256). Biopsy specimens presented lower CYP3A4 expression than normal bone (p=0.0314). The overexpression of both CYP1A2 and CYP3A4 in post-chemotherapy specimens were correlated with better event free-survival (p=0.0244) and good response (p=0.0484), respectively. Furthermore, in vitro assays revealed that CYP1A2 was upregulated by doxorubicin (p=0.0034); CYP3A4 was upregulated by cisplatin, doxorubicin and methotrexate (p=0.0004, p=0.0024, p<0.0001, respectively); and CYP3A5 was downregulated by doxorubicin (p=0.0285) and upregulated in time-dependent manner by methotrexate (p=0.0239). In conclusion, our findings suggest that CYP genes play an important role in OS tumorigenesis, at primary and metastatic sites, as well in treatment response.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15869